Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 6/20 | 0.65 |
| ▸ | PRKCB | P05771 | 5/20 | 0.65 |
| ▸ | PRKCA | P17252 | 5/20 | 0.65 |
| ▸ | PRKCH | P24723 | 5/20 | 0.65 |
| ▸ | PRKCE | Q02156 | 5/20 | 0.65 |
| ▸ | PRKCD | Q05655 | 5/20 | 0.65 |
| ▸ | PRKACA | P17612 | 2/20 | 0.57 |
| ▸ | PRKACG | P22612 | 2/20 | 0.57 |
| ▸ | PRKACB | P22694 | 2/20 | 0.57 |
| ▸ | GSK3B | P49841 | 2/20 | 0.54 |
| ▸ | CAMK2D | Q13557 | 2/20 | 0.53 |
| ▸ | JAK3 | P52333 | 6/20 | 0.50 |
| ▸ | JAK1 | P23458 | 2/20 | 0.49 |
| ▸ | KDR | P35968 | 2/20 | 0.48 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.47 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.47 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | PRKCG | P05129 | 1/20 | 0.47 |
| ▸ | CDK1 | P06493 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6584593 | 0.83 | GSK3B (0.72) | PRKCBPRKCAGSK3BKDRPRKCG | |
| SCHEMBL22566961 | 0.75 | PRKACA (0.91) | PRKCQPRKCBPRKCAPRKCHPRKCE | |
| SCHEMBL6956475 | 0.74 | ADORA2A (0.49) | KDRMAPK9MAPKAPK2 | |
| SCHEMBL6955589 | 0.73 | ADORA2A (0.48) | KDRMAPK9MAPKAPK2CHEK1 | |
| SCHEMBL9085106 | 0.73 | PRKACA (0.73) | PRKCQPRKCBPRKCAPRKCHPRKCE | |
| SCHEMBL9086419 | 0.73 | PRKACA (0.73) | PRKCQPRKCBPRKCAPRKCHPRKCE | |
| SCHEMBL7824089 | 0.73 | PRKACA (1.00) | PRKCQPRKCBPRKCAPRKCHPRKCE | |
| SCHEMBL20387005 | 0.72 | GSK3B (0.73) | PRKCAPRKACAPRKACGPRKACBGSK3B | |
| SCHEMBL7815598 | 0.72 | PRKACA (0.78) | PRKCQPRKCBPRKCAPRKCHPRKCE | |
| SCHEMBL9086502 | 0.72 | PRKACA (0.78) | PRKCQPRKCBPRKCAPRKCHPRKCE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1307447-B1 | 3-INDOLYL-4-PHENYL-1H-PYRROLE-2,5-DIONE DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE KINASE-3BETA | HOFFMANN LA ROCHE (CH) | 2004-12-15 | — | — | EP | disclosed |
| US-20020188018-A1 | 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta | GONG LEYI (US) | 2002-12-12 | — | — | US | disclosed |
| US-6479490-B2 | TREATMENT OF DISEASES CHARACTERIZED BY EXCESS TH2 CYTOKINES AND/ OR AN EXCESS IGE PRODUCTION. | SYNTEX (U.S.A.) LLC | 2002-11-12 | — | — | US | disclosed |
| US-20020052397-A1 | 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta | SYNTEX (U.S.A.) LLC | 2002-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052397-A1 | 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta | GSK3B, GSK3A, PYGL | PRKCQ 135/4885PRKCB 62/4885PRKCA 61/4885 |
| US-20020188018-A1 | 3-indolyl-4-phenyl-1H-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta | GSK3B, GSK3A, PYGL | PRKCQ 144/4885PRKCB 51/4885PRKCA 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.